Stock listing
NASDAQ:CRBU Caribou Biosciences, Inc. Stock
Home listing (NASDAQ) of Caribou Biosciences, Inc.
Follow Caribou Biosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CRBU
$0.284 USD -0.042 (-12.8%)
Close on Nov 20, 2026
- Day range
- $0.282 – $0.305 USDNov 20, 2026
- Volume
- 3.26M sharesNov 20, 2026
- Market cap
- $30.71M USDAt the close on Nov 20, 2026 · price × 108.0M shares outstanding
- 52-week range
- $0.282 – $2.490 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.96M USDMedian day 1.69M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CRBU · Home | $0.284 USD | -0.042 (-12.8%) | 3,256,041 | $0.300 | $0.305 | $0.282 | $0.326 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CRBU · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.284 | -0.042 | -12.8% | $0.300 | $0.305 | $0.282 | 3,256,041 | |
| $0.326 | -0.015 | -4.3% | $0.340 | $0.349 | $0.311 | 3,372,296 | |
| $0.341 | -0.012 | -3.4% | $0.345 | $0.353 | $0.325 | 2,566,359 | |
| $0.353 | -0.009 | -2.5% | $0.360 | $0.365 | $0.350 | 2,149,099 | |
| $0.362 | -0.018 | -4.8% | $0.384 | $0.384 | $0.360 | 1,737,983 | |
| $0.380 | -0.011 | -2.7% | $0.388 | $0.388 | $0.365 | 1,539,115 | |
| $0.391 | -0.020 | -4.8% | $0.400 | $0.404 | $0.365 | 2,939,655 | |
| $0.410 | -0.009 | -2.2% | $0.410 | $0.430 | $0.390 | 1,639,705 | |
| $0.420 | -0.029 | -6.4% | $0.440 | $0.460 | $0.409 | 3,258,357 | |
| $0.449 | +0.036 | +8.8% | $0.401 | $0.449 | $0.401 | 1,702,305 | |
| $0.412 | -0.032 | -7.2% | $0.438 | $0.441 | $0.403 | 1,904,662 | |
| $0.444 | -0.015 | -3.3% | $0.459 | $0.473 | $0.437 | 1,232,951 | |
| $0.459 | +0.019 | +4.4% | $0.427 | $0.465 | $0.415 | 1,379,687 | |
| $0.440 | +0.017 | +3.9% | $0.435 | $0.450 | $0.410 | 3,304,685 | |
| $0.423 | -0.022 | -4.9% | $0.445 | $0.445 | $0.414 | 2,306,242 | |
| $0.445 | -0.044 | -9.1% | $0.487 | $0.500 | $0.445 | 2,837,479 | |
| $0.489 | +0.029 | +6.2% | $0.469 | $0.492 | $0.461 | 1,024,941 | |
| $0.461 | -0.032 | -6.4% | $0.487 | $0.495 | $0.455 | 2,368,163 | |
| $0.492 | -0.041 | -7.6% | $0.533 | $0.536 | $0.491 | 1,934,025 | |
| $0.533 | -0.027 | -4.9% | $0.550 | $0.577 | $0.533 | 2,155,513 | |
| $0.560 | +0.016 | +2.9% | $0.528 | $0.564 | $0.521 | 2,784,450 | |
| $0.544 | +0.025 | +4.9% | $0.520 | $0.550 | $0.512 | 2,264,019 | |
| $0.519 | +0.055 | +11.9% | $0.469 | $0.525 | $0.463 | 3,411,959 | |
| $0.464 | -0.006 | -1.3% | $0.464 | $0.478 | $0.459 | 3,801,304 | |
| $0.470 | +0.005 | +1.1% | $0.470 | $0.478 | $0.449 | 2,945,171 | |
| $0.465 | +0.005 | +1.0% | $0.460 | $0.477 | $0.447 | 2,881,415 | |
| $0.460 | -0.010 | -2.1% | $0.477 | $0.484 | $0.445 | 3,709,542 | |
| $0.470 | -0.027 | -5.4% | $0.482 | $0.495 | $0.450 | 4,546,001 | |
| $0.497 | +0.037 | +8.0% | $0.452 | $0.507 | $0.445 | 5,264,111 | |
| $0.460 | -0.021 | -4.4% | $0.460 | $0.519 | $0.443 | 9,738,162 | |
| $0.481 | -0.136 | -22.1% | $0.594 | $0.597 | $0.450 | 19,344,000 | |
| $0.617 | -0.518 | -45.6% | $0.636 | $0.670 | $0.546 | 37,509,910 | |
| $1.135 | -0.055 | -4.6% | $1.190 | $1.215 | $1.130 | 5,939,336 | |
| $1.190 | -0.030 | -2.5% | $1.220 | $1.240 | $1.170 | 1,546,867 | |
| $1.220 | 0.000 | 0.0% | $1.240 | $1.240 | $1.215 | 866,573 | |
| $1.220 | -0.050 | -3.9% | $1.270 | $1.285 | $1.220 | 687,396 | |
| $1.270 | +0.030 | +2.4% | $1.278 | $1.285 | $1.250 | 845,066 | |
| $1.240 | +0.010 | +0.8% | $1.250 | $1.265 | $1.220 | 637,084 | |
| $1.230 | -0.010 | -0.8% | $1.250 | $1.260 | $1.220 | 818,632 | |
| $1.240 | -0.010 | -0.8% | $1.250 | $1.270 | $1.220 | 901,267 | |
| $1.250 | -0.040 | -3.1% | $1.290 | $1.290 | $1.250 | 978,905 | |
| $1.290 | -0.050 | -3.7% | $1.340 | $1.360 | $1.290 | 700,029 | |
| $1.340 | +0.040 | +3.1% | $1.320 | $1.360 | $1.310 | 1,217,330 | |
| $1.300 | 0.000 | 0.0% | $1.310 | $1.350 | $1.290 | 753,310 | |
| $1.300 | -0.010 | -0.8% | $1.330 | $1.340 | $1.300 | 1,853,974 | |
| $1.310 | +0.060 | +4.8% | $1.270 | $1.330 | $1.260 | 1,257,062 | |
| $1.250 | -0.020 | -1.6% | $1.280 | $1.290 | $1.250 | 969,353 | |
| $1.270 | -0.020 | -1.6% | $1.310 | $1.310 | $1.250 | 1,692,439 | |
| $1.290 | +0.020 | +1.6% | $1.275 | $1.330 | $1.250 | 1,685,847 | |
| $1.270 | -0.100 | -7.3% | $1.380 | $1.400 | $1.260 | 2,433,878 | |
| $1.370 | -0.070 | -4.9% | $1.430 | $1.440 | $1.350 | 1,261,006 | |
| $1.440 | -0.100 | -6.5% | $1.540 | $1.540 | $1.440 | 1,768,265 | |
| $1.540 | -0.030 | -1.9% | $1.570 | $1.580 | $1.540 | 717,627 | |
| $1.570 | 0.000 | 0.0% | $1.570 | $1.600 | $1.550 | 1,329,447 | |
| $1.570 | -0.030 | -1.9% | $1.610 | $1.610 | $1.533 | 1,349,959 | |
| $1.600 | +0.050 | +3.2% | $1.550 | $1.625 | $1.550 | 770,671 | |
| $1.550 | +0.010 | +0.6% | $1.530 | $1.590 | $1.519 | 756,279 | |
| $1.540 | -0.080 | -4.9% | $1.610 | $1.630 | $1.525 | 1,010,331 | |
| $1.620 | -0.040 | -2.4% | $1.660 | $1.670 | $1.600 | 666,589 | |
| $1.660 | +0.010 | +0.6% | $1.670 | $1.690 | $1.640 | 901,154 | |
| $1.650 | -0.110 | -6.3% | $1.750 | $1.750 | $1.640 | 841,305 | |
| $1.760 | +0.120 | +7.3% | $1.650 | $1.760 | $1.650 | 1,380,392 | |
| $1.640 | -0.020 | -1.2% | $1.680 | $1.690 | $1.610 | 762,660 | |
| $1.660 | +0.050 | +3.1% | $1.640 | $1.690 | $1.615 | 1,162,457 | |
| $1.610 | -0.030 | -1.8% | $1.640 | $1.650 | $1.580 | 892,576 |
- Ticker
- NASDAQ:CRBU
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
Caribou Biosciences Reports Third Quarter 2026 Financial Results
Latest deck · Feb 7, 2026
2026 Tandem Meetings
Conference · 19 slides
Latest news
Caribou Biosciences Reports Third Quarter 2026 Financial Results
Nov 5, 2026
Closed $0.449 (+8.8%) on Nov 6, 2026
Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
Nov 4, 2026
Closed $0.444 (-3.3%) on Nov 4, 2026
Caribou Biosciences to Evaluate Strategic Alternatives
Oct 6, 2026
Closed $0.617 (-45.6%) on Oct 7, 2026
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 13, 2026
Closed $1.58 (-1.9%) on Aug 14, 2026
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Jun 29, 2026
Closed $1.77 (+5.4%) on Jun 29, 2026
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
Jun 11, 2026
Closed $1.66 (-7.3%) on Jun 11, 2026
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
May 27, 2026
Closed $2.31 (0.0%) on May 28, 2026
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
May 13, 2026
Closed $2.14 (+0.9%) on May 14, 2026
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
May 12, 2026
Closed $2.03 (0.0%) on May 12, 2026
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Closed $1.94 (+3.2%) on May 8, 2026
Caribou Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 99 in all · newest Nov 5, 2026 · oldest 2021
- Decks
- 13 decks · latest Feb 7, 2026
Where Caribou Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CRBU · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CRBU | BOATS | United States | USD |
Valuation
EV/sales −4.0× against a median of 25.3×: the lowest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$37.75M USD
- P/E
- Loss
- EV/sales
- −4.0×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.4×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.3×
- Beta vs S&P 500
- 1.87
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Caribou Biosciences, Inc. · NASDAQ:CRBU | US$30.71M | −US$37.75M | n/a | −4.0× | n/a | 0.4× | n/a | 0.3× | 1.87 |
| Enimmune Corporation · TPEX:6564 | US$31.74M | US$26.87M | n/a | 18.4× | n/a | 10.4× | −341.0% | 0.3× | n/a |
| Molecure SA · GPW:MOC | US$31.66M | US$29.60M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Isofol Medical AB · OMXSTO:ISOFOL | US$31.12M | US$19.86M | n/a | n/a | n/a | 3.3× | n/a | 0.0× | n/a |
| Sareum Holdings plc · LSE:SAR | US$31.07M | US$27.81M | n/a | n/a | n/a | 19.9× | n/a | 0.0× | n/a |
| Filana Therapeutics, Inc. · NASDAQ:FLNA | US$30.98M | −US$16.01M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.25 |
| Avecho Biotechnology Limited · ASX:AVE | US$30.71M | US$26.48M | n/a | 32.3× | n/a | 24.3× | −356.8% | 0.1× | n/a |
| Kalaris Therapeutics, Inc. · NASDAQ:KLRS | US$30.47M | −US$51.05M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.47 |
| Pacific Software, Inc. · OTC:PFSF | US$29.86M | US$38.10M | n/a | n/a | n/a | n/a | n/a | n/a | 1.57 |
| NextCure, Inc. · NASDAQ:NXTC | US$29.53M | US$20.81M | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.85 |
| NurExone Biologic Inc · TSXV:NRX | US$29.53M | US$28.52M | n/a | n/a | n/a | 23.3× | n/a | 0.0× | 0.00 |
| Median of the others | US$30.85M | US$26.68M | 25.3× | 5.4× | −348.9% | 0.0× | 1.25 |
Forecasts
1 strong buy · 4 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 5.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.03 · 4 analysts
- Revenue, year to Dec 2026
- 25.72M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Dara Richardson-Heron | Chief Executive Officer |
| Nancy Whiting | President and Chief Executive Officer |
| Rachel Haurwitz | President and chief executive officer |
| Ran Zheng | Chief Executive Officer |
| Andrew Guggenhime | President and Chief Financial Officer |
| Sri Ryali | Chief Financial Officer |
| David Johnson | Chief Operating Officer |
| Barbara McClung | Chief Legal Officer and Corporate Secretary |
| Enrique Zudaire | Senior Vice President, Translational Research |
| Justin Skoble | Senior Vice President, Technical Operations |
| Reigin Zawadzki | Chief People Officer |
| Tina Albertson | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Andrew Guggenhime | President and Chief Financial Officer |
| Dara Richardson-Heron | Chief Executive Officer |
| David Johnson | Chief Operating Officer |
| Nancy Whiting | President and Chief Executive Officer |
| Natalie Sacks | Partner at Novo Holdings Ventures Investment |
| Rachel Haurwitz | President and chief executive officer |
| Ran Zheng | Chief Executive Officer |
| Scott Braunstein | Operating Partner |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +8.8% |
| Q2 2026 | Aug 13, 2026 · After close | −1.9% |
| Q1 2026 | May 7, 2026 · After close | +3.2% |
| Q4 2025 | Mar 16, 2026 | +4.8% |
| Q3 2025 | Nov 12, 2025 · After close | −12.2% |
| Q2 2025 | Aug 12, 2025 · After close | +8.9% |
| Q1 2025 | May 8, 2025 · After close | −2.0% |
| Q4 2024 | Mar 10, 2025 | −7.8% |
| Q3 2024 | Nov 6, 2024 · After close | +1.1% |
| Q2 2024 | Aug 6, 2024 · After close | −2.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | −6.2% |
| Q4 2023 | Mar 11, 2024 · After close | −30.5% |
| Q3 2023 | Nov 7, 2023 · After close | −5.0% |
| Q2 2023 | Aug 8, 2023 · After close | +5.8% |
| Q1 2023 | May 9, 2023 · After close | +6.8% |
| Q4 2022 | Mar 9, 2023 · After close | −6.0% |
| Q3 2022 | Nov 8, 2022 · After close | +0.8% |
| Q2 2022 | Aug 9, 2022 · After close | +14.3% |
| Q1 2022 | May 9, 2022 · After close | +9.3% |
| Q4 2021 | Mar 21, 2022 · After close | +9.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 2026 Tandem Meetings | Conference | 19 slides | Feb 7, 2026 |
| Technical Presentation (2026) | Technical | 16 slides | 2026 |
| EHA 2026 | Conference | 16 slides | 2026 |
| Technical Presentation (June 2024) | Technical | 47 slides | Jun 3, 2024 |
| Technical Presentation (June 2024) | Technical | 47 slides | Jun 2, 2024 |
| Investor Presentation (May 2024) | Investor deck | 46 slides | May 7, 2024 |
| Technical Presentation (April 2024) | Technical | 12 slides | Apr 20, 2024 |
| Corporate Update (April 2024) | Corporate update | 19 slides | Apr 4, 2024 |
| Corporate Update (July 2023) | Corporate update | 36 slides | Jul 13, 2023 |
| Technical Presentation (July 2023) | Technical | 37 slides | Jul 13, 2023 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (July 2023) | Technical | 11 slides | Jul 13, 2023 |
| Technical Presentation (June 2022) | Technical | 31 slides | Jun 10, 2022 |
| Corporate Update (May 2022) | Corporate update | 19 slides | May 12, 2022 |
IPO
Priced at US$16.00 a share on Jul 22, 2021.
- Price
- US$16.00 a share
- Shares offered
- 19,000,000 shares of common stock
- Offering size
- US$304 million
- Underwriters' option
- Up to 2,850,000 more shares
- Underwriters
- BofA Securities, Citigroup, SVB Leerink · In the order on the cover
- Shares delivered
- On or about Jul 27, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 7, 2021 |
| Filed publicly | Jul 1, 2021 |
| Amended twice | Newest Jul 22, 2021 |
| Shares registered with an exchange | Jul 19, 2021 |
| Declared effective by the SEC | Jul 22, 2021 |
| Final prospectus, with the price | Jul 23, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 23, 2021 |
| EFFECT · Notice that a registration is effective | Jul 22, 2021 |
| S-1MEF · Registration of more shares for the same offering | Jul 22, 2021 |
| FWP · Free writing prospectus | Jul 22, 2021 |
| S-1/A · Registration statement, amended | Jul 22, 2021 |
| CERT · Exchange's certificate of listing | Jul 21, 2021 |
| CORRESP · Letter to the SEC | Jul 20, 2021 |
| CORRESP · Letter to the SEC | Jul 20, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 19, 2021 |
| S-1/A · Registration statement, amended | Jul 19, 2021 |
All 18 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jul 12, 2021 |
| CORRESP · Letter to the SEC | Jul 1, 2021 |
| S-1 · Registration statement | Jul 1, 2021 |
| UPLOAD · Letter from the SEC | Jun 23, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jun 11, 2021 |
| DRS/A · Draft registration statement, amended | Jun 11, 2021 |
| UPLOAD · Letter from the SEC | Jun 2, 2021 |
| DRS · Draft registration statement | May 7, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 23, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 11.2M | 9.99M | 34.5M | 13.9M | 9.60M | 12.4M | 5.79M |
| Cost of revenue | 3.65M | 3.93M | 3.52M | 3.64M | 984.0K | 34.4M | 23.6M |
| Gross profit | 7.51M | 6.07M | 31.0M | 10.2M | 8.61M | -22.1M | 5.79M |
| Research and development | 109.4M | 130.2M | 112.1M | 82.2M | 52.3M | 34.4M | 23.6M |
| Selling, general and administrative | 37.9M | 46.5M | 38.5M | 38.0M | 24.3M | 14.1M | 16.5M |
| Operating income | -148.3M | -166.6M | -116.1M | -106.4M | -67.0M | -36.1M | -34.3M |
| Depreciation and amortization | 3.65M | 3.93M | 3.52M | 1.62M | 984.0K | 900.0K | 751.0K |
| EBITDA | -144.7M | -162.7M | -112.5M | -104.8M | -66.0M | -35.2M | -33.6M |
| Interest expense | 8.54M | 8.00K | 20.0K | 4.00K | |||
| Income before tax | -148.7M | -149.1M | -101.9M | -99.4M | -66.6M | -36.1M | -31.0M |
| Income tax | -550.0K | -9.00K | 193.0K | 70.0K | 321.0K | -1.82M | -7.54M |
| Net income | -148.1M | -149.1M | -102.1M | -99.4M | -66.9M | -34.3M | -23.4M |
| Earnings per share, basic | -1.59 | -1.65 | -1.38 | -1.64 | -2.11 | -4.01 | -2.80 |
| Earnings per share, diluted | -1.59 | -1.65 | -1.38 | -1.64 | -2.11 | -4.01 | -2.80 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 12.4M | 16.3M | 51.2M | 58.3M | 240.4M | 16.0M | 41.1M |
| Short-term investments | 127.0M | 193.2M | 277.7M | 189.3M | 135.4M | 0 | 8.40M |
| Receivables | 69.0K | 265.0K | 148.0K | 202.0K | 1.15M | 150.0K | 3.98M |
| Inventory | -62.6M | -31.1M | 2.43M | 3.18M | |||
| Current assets | 145.2M | 219.4M | 338.8M | 260.2M | 391.2M | 24.3M | 57.0M |
| Property, plant and equipment | 6.76M | 19.3M | 18.3M | 10.7M | 4.89M | 3.50M | 4.33M |
| Total assets | 175.4M | 313.3M | 432.2M | 373.8M | 442.4M | 36.0M | 61.9M |
| Accounts payable | 5.78M | 2.48M | 3.12M | 1.15M | 3.99M | 2.60M | 2.54M |
| Current liabilities | 25.4M | 30.7M | 28.3M | 28.1M | 25.8M | 12.4M | 10.1M |
| Long-term debt | 924.0K | ||||||
| Total debt | 27.2M | 26.5M | 27.1M | 27.7M | 259.0K | 1.58M | 532.0K |
| Total liabilities | 53.2M | 60.4M | 63.8M | 72.9M | 54.5M | 18.2M | 54.5M |
| Shareholders' equity | 122.2M | 253.0M | 368.4M | 300.9M | 387.8M | -23.4M | 7.46M |
| Shares outstanding | 95.1M | 92.4M | 88.4M | 61.0M | 60.3M | 9.71M | 60.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -111.0M | -138.2M | -93.3M | -91.0M | -32.5M | -33.2M | -32.0M |
| Capital spending | -1.36M | -4.88M | -11.6M | -6.45M | -2.12M | -317.0K | -884.0K |
| Free cash flow | -112.4M | -143.1M | -104.9M | -97.4M | -34.6M | -33.5M | -32.9M |
| Cash from investing | 102.2M | 86.6M | -68.2M | -93.2M | -176.4M | 6.36M | 27.2M |
| Cash from financing | 4.82M | 16.7M | 154.3M | 2.13M | 433.4M | 1.74M | 172.0K |
| Share buybacks | 432.4M | ||||||
| Change in cash | -3.93M | -34.9M | -7.18M | -182.1M | 224.5M | -25.1M | -4.60M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 8-K · Current report | Oct 6, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 18, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 11, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Jun 5, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | May 7, 2026 | Results | SEC |
| DEFR14A | May 1, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 10, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 31, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Nov 3, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 23, 2025 | Current report | SEC |
| 8-K · Current report | Jun 13, 2025 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | May 15, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 13, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 12, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | May 8, 2025 | Meeting notice | SEC |
| S-3 · Registration statement | May 8, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Apr 25, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 24, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 11, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 10, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 10, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 2, 2025 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 17, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Oct 4, 2024 | Insider trade | SEC |
| 8-K/A · Current report, amended | Sep 27, 2024 | Management or board change | SEC |
| 8-K · Current report | Sep 3, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 8-K · Current report | Jul 16, 2024 | Results | SEC |
| 8-K · Current report | Jun 14, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 3, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 25, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 4, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 11, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 11, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Feb 23, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 8, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 25, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 25, 2024 | Big-stake notice | SEC |
| 3/A · Initial statement of ownership, amended | Jan 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 9, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jan 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| 8-K · Current report | Dec 22, 2023 | Management or board change | SEC |
| 8-K · Current report | Dec 12, 2023 | Management or board change | SEC |
| 10-Q/A · Quarterly report, amended | Nov 17, 2023 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Nov 17, 2023 | Quarterly report | SEC |
| 10-Q · Quarterly report | Nov 7, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2023 | Results | SEC |
| 8-K · Current report | Oct 18, 2023 | Current report | SEC |
| 8-K · Current report | Sep 26, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2023 | Results | SEC |
| SC 13G · Big-stake notice | Jul 20, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jul 14, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Jul 14, 2023 | Offer document | SEC |
| 8-K/A · Current report, amended | Jul 14, 2023 | Current report | SEC |
| 424B5 · Prospectus | Jul 13, 2023 | Offer document | SEC |
| 8-K · Current report | Jul 13, 2023 | Results | SEC |
| 8-K · Current report | Jul 13, 2023 | Current report | SEC |
| SC 13G · Big-stake notice | Jul 10, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jul 6, 2023 | Material contract | SEC |
| 8-K · Current report | Jun 16, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 9, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2023 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 8-K · Current report | Apr 4, 2023 | Current report | SEC |
| 8-K · Current report | Mar 29, 2023 | Current report | SEC |
| 8-K · Current report | Mar 29, 2023 | Current report | SEC |
| 8-K · Current report | Mar 24, 2023 | Current report | SEC |
| 4 · Change in ownership | Mar 22, 2023 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 9, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 9, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2023 | Results | SEC |
| 4 · Change in ownership | Feb 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 3, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 3, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 20, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 16, 2022 | Management or board change | SEC |
| 8-K · Current report | Dec 12, 2022 | Current report | SEC |
| 4 · Change in ownership | Dec 2, 2022 | Insider trade | SEC |
| 8-K · Current report | Nov 29, 2022 | Current report | SEC |
| 8-K · Current report | Nov 21, 2022 | Current report | SEC |
| 10-Q · Quarterly report | Nov 8, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2022 | Results | SEC |
| 8-K · Current report | Nov 3, 2022 | Current report | SEC |
| 8-K · Current report | Oct 18, 2022 | Current report | SEC |
| 4 · Change in ownership | Oct 7, 2022 | Insider trade | SEC |
| 8-K/A · Current report, amended | Sep 22, 2022 | Meeting outcome | SEC |
This page holds 200 of 326 filings. Open Filings
Cap table
Built by 6ix from Caribou Biosciences, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 108,036,729
- Fully diluted
- 108,036,729
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 108,036,729 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 108,036,729 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Scott Braunstein Other companies: AtaiBeckley Inc. (Director · Since at least Jun 4, 2026); RAPT Therapeutics Inc (Director · Since at least Jun 21, 2025); Trevena, Inc. (Operating Partner at Aisling Capital Management LP · Since at least Sep 27, 2018); Protara Therapeutics, Inc. (Director · Jan 9, 2020 – Jun 9, 2020 · Past); Constellation Pharmaceuticals Inc (Director · Feb 19, 2019 – Jul 15, 2021 · Past); Marinus Pharmaceuticals Inc (CHAIRMAN AND CEO, Director · Sep 19, 2018 – Aug 14, 2024 · Past); Alaunos Therapeutics, Inc. (Director · Sep 18, 2018 – Dec 31, 2019 · Past); Pacira BioSciences, Inc. (Chief Operating Officer · Jul 13, 2015 – Jan 3, 2018 · Past); Esperion Therapeutics, Inc. (Director · Jun 15, 2015 – May 29, 2019 · Past) | Operating Partner · Since at least Jul 22, 2021 |
| David Johnson Other companies: Vera Therapeutics, Inc. (Chief Operating Officer · Since at least Jul 1, 2024); Exelixis, Inc. (Director · Since at least May 31, 2023); Aura Biosciences, Inc. (Chairman · Since at least Oct 28, 2021); Liquidia Corporation (Board Member · Since at least Apr 13, 2021); Zentalis Pharmaceuticals, Inc. (Director · Since at least Apr 3, 2020); AMAG Pharmaceuticals Inc (Director · Oct 8, 2019 – Nov 16, 2020 · Past); Dynavax Technologies Corporation (Vice President · Jun 2, 2019 – Mar 13, 2020 · Past); Global Blood Therapeutics Inc (Chief Commercial Officer · Mar 13, 2018 – Oct 5, 2022 · Past) | Chief Operating Officer · Since at least May 11, 2022 |
| Andrew Guggenhime Other companies: Vaxcyte, Inc. (PRESIDENT AND CFO · Since at least Jun 11, 2020); Metacrine Inc (Director · Sep 15, 2020 – May 18, 2022 · Past); Facet Biotech Corp (SVP & CFO · Dec 9, 2008 – Apr 21, 2010 · Past); PDL BioPharma Inc (SVP & Chief Financial Officer · Apr 3, 2006 – Dec 18, 2008 · Past); Neoforma Inc (Chief Financial Officer · Dec 31, 2005 – Dec 31, 2005 · Past) | President and Chief Financial Officer · Since at least Jul 22, 2021 |
| Natalie Sacks Other companies: Harpoon Therapeutics Inc (Chief Medical Officer · Feb 7, 2019 – Jan 28, 2022 · Past); Zymeworks Inc. (Director · Jan 1, 2019 – Dec 21, 2022 · Past); Aduro Biotech Inc (Chief Medical Officer · Aug 31, 2016 – Sep 12, 2018 · Past) | Partner at Novo Holdings Ventures Investment · Since at least Jul 22, 2021 |
| Jason V. O'Byrne Other companies: Olema Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Aug 11, 2026); Vir Biotechnology, Inc. (EVP & Chief Financial Officer · Since at least Oct 2, 2024) | Chief Financial Officer · Jul 22, 2021 – Feb 20, 2024 · Past |
| Rachel Haurwitz Other companies: Seer, Inc. (Director · Nov 8, 2021 – Jun 12, 2024 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 11, 2016 · Past) | President and chief executive officer · Since at least Jul 22, 2021 |
| Sriram Ryali Other companies: Codexis, Inc. (Chief Financial Officer · Jan 23, 2023 – Jan 1, 2024 · Past); Eiger Biopharmaceuticals Inc (Chief Financial Officer · Dec 17, 2018 – Mar 14, 2022 · Past) | Chief Financial Officer · Since at least Jan 2, 2025 |
| Syed Ali-aamir Rizvi Other companies: Rocket Pharmaceuticals, Inc. (Chief Medical Officer · Since at least Sep 15, 2025); Poseida Therapeutics Inc (Chief Medical Officer · Apr 1, 2024 – Jan 8, 2025 · Past) | Chief Medical Officer · Jan 18, 2022 – Feb 21, 2023 · Past |
| Nancy Whiting Other companies: Boundless Bio, Inc. (Director · Since at least Mar 27, 2024) | President and Chief Executive Officer · Since at least Aug 24, 2021 |
| Timothy P Kelly Other companies: Q32 Bio Inc. (Chief Operating Officer · Sep 20, 2018 – Feb 24, 2022 · Past) | Chief Technology Officer · Since at least Jan 1, 2024 |
All 23 people
| Person | Seat |
|---|---|
| Tina M Albertson Other companies: Lyell Immunopharma, Inc. (Chief Medical Officer · Mar 23, 2022 – Feb 24, 2023 · Past) | Chief Medical Officer · Since at least Aug 12, 2024 |
| Barbara McClung | Chief Legal Officer and Corporate Secretary · Since at least Jul 22, 2021 |
| Dara Richardson-Heron | Chief Executive Officer · Since at least Nov 4, 2021 |
| Enrique Zudaire | Senior Vice President, Translational Research · Since at least Nov 4, 2026 |
| Jeffrey Stephen Long-McGie | Director · Jul 22, 2021 – Jul 22, 2021 · Past |
| Justin Skoble | Senior Vice President, Technical Operations · Since at least Nov 4, 2026 |
| Ran Zheng | Chief Executive Officer · Since at least Sep 24, 2021 |
| Reigin Zawadzki | Chief People Officer · Since at least Nov 4, 2026 |
| Ruhi Ahmad Khan | Chief Business Officer · Since at least Nov 8, 2021 |
| Ryan Fischesser | VP of Finance and Controller · Jul 22, 2021 – Nov 20, 2024 · Past |
| Sri Ryali | Chief Financial Officer · Since at least Jan 12, 2025 |
| Steven Kanner | Chief Scientific Officer · Jul 22, 2021 – Feb 20, 2025 · Past |
| Tina Albertson | Chief Medical Officer · Since at least Mar 31, 2026 |
Log in to ask 6ix AI your own questions about Caribou Biosciences, Inc.